Skip to main content

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, May 3 '25)

Image
By G.M.

 


    Arch Virol

  1. SVYATCHENKO SV, Boldyrev ND, Panova AS, Kolosova NP, et al
    Seroprevalence of anti-influenza antibodies in humans and characterization of seasonal influenza viruses isolated in Russia during the 2023-2024 flu season.
    Arch Virol. 2025;170:118.
    PubMed         Abstract available


    Biochem Biophys Res Commun

  2. CHU X, Yang Y, Guo H, Ji X, et al
    SARS-CoV-2 NSP2 specifically interacts with cellular protein SmgGDS.
    Biochem Biophys Res Commun. 2025;764:151828.
    PubMed         Abstract available

  3. ZHANG YH, Su AM, Hou XM
    Structural and functional insights into the SARS-CoV-2 SUD domain and its interaction with RNA G-Quadruplexes.
    Biochem Biophys Res Commun. 2025;764:151817.
    PubMed         Abstract available


    Epidemiol Infect

  4. STERIAN M, Naganathan T, Corrin T, Waddell L, et al
    Evidence on the associations and safety of COVID-19 vaccination and post COVID-19 condition: an updated living systematic review.
    Epidemiol Infect. 2025;153:e62.
    PubMed         Abstract available


    J Gen Virol

  5. ARANDA AJ, Aguilar-Tipacamu G, Perez DR, Banuelos-Hernandez B, et al
    Emergence, migration and spreading of the high pathogenicity avian influenza virus H5NX of the Gs/Gd lineage into America.
    J Gen Virol. 2025;106:002081.
    PubMed         Abstract available


    J Infect

  6. CARSTENS G, Kozanli E, Bulsink K, McDonald S, et al
    Co-infection dynamics of SARS-CoV-2 and respiratory viruses in the 2022/2023 respiratory season in the Netherlands.
    J Infect. 2025 Mar 21:106474. doi: 10.1016/j.jinf.2025.106474.
    PubMed         Abstract available

  7. WARD T, Paton RS, Overton CE, Mellor J, et al
    Understanding the Effectiveness of the Comirnaty Monovalent and Bivalent Vaccines During the Winter Coronavirus (COVID-19) Infection Survey.
    J Infect. 2025 Mar 5:106461. doi: 10.1016/j.jinf.2025.106461.
    PubMed         Abstract available


    Pediatrics

  8. LOVEDAY T, da Hora C, Wells R, Chorny L, et al
    11-Year-Old Boy With B-ALL-Induced Hypereosinophilic Syndrome Presenting as Acute Encephalopathy.
    Pediatrics. 2025;155:e2024068064.
    PubMed         Abstract available

  9. BAHADIR Z, Narayan P, Wolters R, Permar SR, et al
    Monoclonal Antibodies for Pediatric Viral Disease Prevention and Treatment.
    Pediatrics. 2025;155:e2024068690.
    PubMed         Abstract available

  10. ZHANG L, Wang Y, Berger LM
    State-Based Eviction Moratoria and Child Maltreatment During the COVID-19 Pandemic.
    Pediatrics. 2025;155:e2024068174.
    PubMed         Abstract available

  11. BANDELL A, Giles L, Cervelo Bouzo P, Sibbring GC, et al
    Safety of LAIV Vaccination in Asthma or Wheeze: A Systematic Review and GRADE Assessment.
    Pediatrics. 2025 Apr 24:e2024068459. doi: 10.1542/peds.2024-068459.
    PubMed         Abstract available


    PLoS Biol

  12. KUBINSKI HC, Despres HW, Johnson BA, Schmidt MM, et al
    Variant mutation G215C in SARS-CoV-2 nucleocapsid enhances viral infection via altered genomic encapsidation.
    PLoS Biol. 2025;23:e3003115.
    PubMed         Abstract available


    PLoS Comput Biol

  13. HODCROFT EB, Wohlfender MS, Neher RA, Riou J, et al
    Estimating Re and overdispersion in secondary cases from the size of identical sequence clusters of SARS-CoV-2.
    PLoS Comput Biol. 2025;21:e1012960.
    PubMed         Abstract available


    PLoS One

  14. WITEK TJ JR, Sheikhan NY, Tran A
    Sensory effects of COVID-19 in wine professionals.
    PLoS One. 2025;20:e0321502.
    PubMed         Abstract available

  15. MARSIGLIA MD, Bianchi S, Bai F, Tincati C, et al
    Effectiveness of Anti-SARS-CoV-2 monoclonal antibodies in real-life: RNAemia and clinical outcomes in high-risk COVID-19 patients.
    PLoS One. 2025;20:e0321356.
    PubMed         Abstract available

  16. VANOUDENHOVE J, Liu Y, Nelakanti R, Kim D, et al
    Impact of memory T cells on SARS-CoV-2 vaccine response in hematopoietic stem cell transplant.
    PLoS One. 2025;20:e0320744.
    PubMed         Abstract available

  17. GHIROTTO L, De Panfilis L, Perin M, Miraglia Raineri A, et al
    Psycho-oncology practice for cancer patients during the pandemic lockdown in Italy: A qualitative mixed-method study with psychotherapists.
    PLoS One. 2025;20:e0318241.
    PubMed         Abstract available

  18. MOTIEI M, Hassanzadeh Rad A, Badeli H, Bayat R, et al
    Hospitalization dynamics during COVID-19: Insights into disease trends and patient outcomes.
    PLoS One. 2025;20:e0321269.
    PubMed         Abstract available

  19. ROSA S, Pulido MA, Ruiz JJ, Cocucci TJ, et al
    Transmission matrix parameter estimation of COVID-19 evolution with age compartments using ensemble-based data assimilation.
    PLoS One. 2025;20:e0318426.
    PubMed         Abstract available

  20. CHEN Q, Mat Sin NSB, Mohd Isa ANB, Chen D, et al
    Investigation on the association between college students' smartphone-related behaviors and sleep quality during COVID-19.
    PLoS One. 2025;20:e0321060.
    PubMed         Abstract available

  21. LOHINIVA AL, Lehtinen JM, Arifulla D, Ollgren J, et al
    Factors influencing healthcare workers' compliance with personal protective equipment guidelines in long-term care during the COVID-19 pandemic-A theory-based mixed-methods study.
    PLoS One. 2025;20:e0321851.
    PubMed         Abstract available

  22. SCHAEFER CM, Krause TM, Delclos GL, Greenberg RS, et al
    Risk of post-acute symptoms among adults: A comparison study of severe COVID-19, pneumonia, and influenza.
    PLoS One. 2025;20:e0322020.
    PubMed         Abstract available

  23. WU R, He Y, Teng Z
    Energy price instability and energy efficiency: Korea's macroeconomic framework during the COVID-19 pandemic.
    PLoS One. 2025;20:e0321793.
    PubMed         Abstract available

  24. GEBEYEHU DT, East L, Wark S, Islam MS, et al
    Food safety practices of individuals before and after the emergence of COVID-19: A pre- and post-comparative analysis.
    PLoS One. 2025;20:e0322235.
    PubMed         Abstract available

  25. CARPALLO-PORCAR B, Jimenez-Sanchez C, Calvo S, Irun P, et al
    ARACOV-02. Specialized nutritional intervention and telerehabilitation in patients with long COVID: Protocol of a randomized controlled trial.
    PLoS One. 2025;20:e0321811.
    PubMed         Abstract available

  26. OKMI M, Ang TF, Mohd Zaki MF, Ku CS, et al
    Mobile Phone Network Data in the COVID-19 era: A systematic review of applications, socioeconomic factors affecting compliance to non-pharmaceutical interventions, privacy implications, and post-pandemic economic recovery strategies.
    PLoS One. 2025;20:e0322520.
    PubMed         Abstract available

  27. DENNIS A, Joseph J, Greenwell K, Miller S, et al
    A qualitative process evaluation of a nasal spray intervention to prevent respiratory tract infections.
    PLoS One. 2025;20:e0321314.
    PubMed         Abstract available

  28. SHRESTHA S, Jha P, Shrestha L, Chaudhary LB, et al
    Trend of influenza before and during the COVID-19 pandemic in Nepal-A study from 2018 to 2022.
    PLoS One. 2025;20:e0299610.
    PubMed         Abstract available

  29. FARUK MO, Siddik MAB, Chowdhury KUA, Bari N, et al
    Mental health of persons with disabilities during the COVID-19 pandemic in Bangladesh.
    PLoS One. 2025;20:e0322218.
    PubMed         Abstract available

  30. HIRANBURANA N, Thippamom N, Avihingsanon A, Wacharapluesadee S, et al
    Differential immunogenicity in people living with HIV with varying CD4 levels after bivalent mRNA COVID-19 booster vaccination.
    PLoS One. 2025;20:e0317940.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  31. GRANULO A, Fuchs C, Bohm R
    Psychological reactance to system-level policies before and after their implementation.
    Proc Natl Acad Sci U S A. 2025;122:e2409907122.
    PubMed         Abstract available

  32. CHI G, Abel GJ, Johnston D, Giraudy E, et al
    Measuring global migration flows using online data.
    Proc Natl Acad Sci U S A. 2025;122:e2409418122.
    PubMed         Abstract available


    Vaccine

  33. SINGLETON KL, Post DJ, Augustine AD, Ison MG, et al
    Collaborative influenza vaccine innovation centers (CIVICs) program.
    Vaccine. 2025;54:127118.
    PubMed         Abstract available

  34. ESSINK BJ, Vermeulen W, Andrade C, de Rooij R, et al
    Corrigendum to 'A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older' Vaccine 51 (2025) 126791.
    Vaccine. 2025;56:127127.
    PubMed        

  35. FATIMAH MNN, Thian BYZ, Wong CL, Ong HK, et al
    Chimeric virus-like particles of nodavirus displaying M2e of human and avian influenza A viruses as a potential dual-use vaccine: Inducing a broader immune response and protecting mice against viral infections.
    Vaccine. 2025;56:127165.
    PubMed         Abstract available

  36. BUSTAMANTE Q, Sparkes D, Findlater L, Munro K, et al
    Understanding occupational and attitudinal factors influencing UK healthcare worker decisions for COVID-19 and influenza vaccination: A cross-sectional survey within SIREN.
    Vaccine. 2025;56:127160.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »